These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30445280)

  • 1. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
    Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
    Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
    D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
    J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerenkov luminescence imaging of medical isotopes.
    Ruggiero A; Holland JP; Lewis JS; Grimm J
    J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.
    Wiehr S; Bühler P; Gierschner D; Wolf P; Rolle AM; Kesenheimer C; Pichler BJ; Elsässer-Beile U
    Prostate; 2014 May; 74(7):743-55. PubMed ID: 24610028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
    Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
    Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of
    Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
    J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    Timmermand OV; Tran TA; Strand SE; Axelsson J
    J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
    Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
    Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Costa PF; Püllen L; Kesch C; Krafft U; Tschirdewahn S; Moraitis A; Radtke JP; Ting S; Nader M; Wosniack J; Kersting D; Lückerath K; Herrmann K; Fendler WP; Hadaschik BA; Darr C
    J Nucl Med; 2023 Apr; 64(4):598-604. PubMed ID: 36357181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA.
    Alt K; Wiehr S; Ehrlichmann W; Reischl G; Wolf P; Pichler BJ; Elsässer-Beile U; Bühler P
    Prostate; 2010 Sep; 70(13):1413-21. PubMed ID: 20687214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraoperative
    Darr C; Harke NN; Radtke JP; Yirga L; Kesch C; Grootendorst MR; Fendler WP; Costa PF; Rischpler C; Praus C; Haubold J; Reis H; Hager T; Herrmann K; Binse I; Hadaschik B
    J Nucl Med; 2020 Oct; 61(10):1500-1506. PubMed ID: 32060212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
    Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PSMA
    Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
    J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
    Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.